Nv
Nvelop Ther
Cambridge MAFounded 202030 employees
Private CapbiotechPrivateGenetic Medicine
Platform: LNP Delivery
Market Cap
N/A
All Drugs
4
Clinical Trials
9
Failed / Terminated
3
FDA Approved
2
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Elrabrutinib | NVE-3139 | Phase 3 | 3 | CD19 | Cervical Ca | ||
| NVE-9059 | NVE-9059 | Approved | 3 | IL-23 | CLLADHD | ||
| NVE-9277 | NVE-9277 | Phase 2 | 1 | IL-17A | SMAWet AMD | ||
| Talatinib | NVE-7711 | Approved | 2 | WEE1 | Gastric CaMCC |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (7)